Use of Biocompatible Sorafenib-gold Nanoconjugates for Reversal of Drug Resistance in Human Hepatoblatoma Cells

Abstract The present study identifies the potential of highly biocompatible SF-GNP nano-conjugate to enhance the chemotherapeutic response to combat drug resistance in cancer cells. We developed a stable colloidal suspension of sorafenib-gold nanoconjugate (SF-GNP) of <10 nm size in aqueous mediu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sandeep Kumar Vishwakarma, Priyanka Sharmila, Avinash Bardia, Lakkireddy Chandrakala, N. Raju, G. Sravani, B. V. S. Sastry, Md Aejaz Habeeb, Aleem Ahmed Khan, Marshal Dhayal
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/d0e4b84a554d47299fdab6cb2a459a2a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d0e4b84a554d47299fdab6cb2a459a2a
record_format	dspace
spelling	oai:doaj.org-article:d0e4b84a554d47299fdab6cb2a459a2a2021-12-02T12:32:39ZUse of Biocompatible Sorafenib-gold Nanoconjugates for Reversal of Drug Resistance in Human Hepatoblatoma Cells10.1038/s41598-017-08878-y2045-2322https://doaj.org/article/d0e4b84a554d47299fdab6cb2a459a2a2017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-08878-yhttps://doaj.org/toc/2045-2322Abstract The present study identifies the potential of highly biocompatible SF-GNP nano-conjugate to enhance the chemotherapeutic response to combat drug resistance in cancer cells. We developed a stable colloidal suspension of sorafenib-gold nanoconjugate (SF-GNP) of <10 nm size in aqueous medium for reverting the cancer drug resistance in SF-resistant HepG2 cells in a 3D ex-vivo model system. In-vivo biocompatibility assay of SF-GNPs showed absence of systemic toxicological effects including hematological, biochemical and histological parameters. More importantly, the histopathological analysis of vital organs such as liver, brain, lung, kidney and heart showed very least or no sign of inflammation, cell infiltration, necrosis, tissue disorganization or fibrotic reactions after intra-peritoneal administration of SF-GNP nanoconjugates in animals. However, SF-GNP nanoconjugates significantly reduced (>80%) the percentage cell survival and the size and number of SF resistant solid tumor colonies of HepG2 cells in 3D model system. The exposure of SF-GNP nanoconjugate to SF resistant HepG2 cell colonies also provided evidence for anti-proliferative effect and reversal of drug resistance by elucidating the molecular regulatory mechanisms of extracellular matrix factor (CD147), tumor growth factor (TGF-β), hepatoma upregulated protein (hURP) and drug transporter (ABCG-2).Sandeep Kumar VishwakarmaPriyanka SharmilaAvinash BardiaLakkireddy ChandrakalaN. RajuG. SravaniB. V. S. SastryMd Aejaz HabeebAleem Ahmed KhanMarshal DhayalNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Sandeep Kumar Vishwakarma Priyanka Sharmila Avinash Bardia Lakkireddy Chandrakala N. Raju G. Sravani B. V. S. Sastry Md Aejaz Habeeb Aleem Ahmed Khan Marshal Dhayal Use of Biocompatible Sorafenib-gold Nanoconjugates for Reversal of Drug Resistance in Human Hepatoblatoma Cells
description	Abstract The present study identifies the potential of highly biocompatible SF-GNP nano-conjugate to enhance the chemotherapeutic response to combat drug resistance in cancer cells. We developed a stable colloidal suspension of sorafenib-gold nanoconjugate (SF-GNP) of <10 nm size in aqueous medium for reverting the cancer drug resistance in SF-resistant HepG2 cells in a 3D ex-vivo model system. In-vivo biocompatibility assay of SF-GNPs showed absence of systemic toxicological effects including hematological, biochemical and histological parameters. More importantly, the histopathological analysis of vital organs such as liver, brain, lung, kidney and heart showed very least or no sign of inflammation, cell infiltration, necrosis, tissue disorganization or fibrotic reactions after intra-peritoneal administration of SF-GNP nanoconjugates in animals. However, SF-GNP nanoconjugates significantly reduced (>80%) the percentage cell survival and the size and number of SF resistant solid tumor colonies of HepG2 cells in 3D model system. The exposure of SF-GNP nanoconjugate to SF resistant HepG2 cell colonies also provided evidence for anti-proliferative effect and reversal of drug resistance by elucidating the molecular regulatory mechanisms of extracellular matrix factor (CD147), tumor growth factor (TGF-β), hepatoma upregulated protein (hURP) and drug transporter (ABCG-2).
format	article
author	Sandeep Kumar Vishwakarma Priyanka Sharmila Avinash Bardia Lakkireddy Chandrakala N. Raju G. Sravani B. V. S. Sastry Md Aejaz Habeeb Aleem Ahmed Khan Marshal Dhayal
author_facet	Sandeep Kumar Vishwakarma Priyanka Sharmila Avinash Bardia Lakkireddy Chandrakala N. Raju G. Sravani B. V. S. Sastry Md Aejaz Habeeb Aleem Ahmed Khan Marshal Dhayal
author_sort	Sandeep Kumar Vishwakarma
title	Use of Biocompatible Sorafenib-gold Nanoconjugates for Reversal of Drug Resistance in Human Hepatoblatoma Cells
title_short	Use of Biocompatible Sorafenib-gold Nanoconjugates for Reversal of Drug Resistance in Human Hepatoblatoma Cells
title_full	Use of Biocompatible Sorafenib-gold Nanoconjugates for Reversal of Drug Resistance in Human Hepatoblatoma Cells
title_fullStr	Use of Biocompatible Sorafenib-gold Nanoconjugates for Reversal of Drug Resistance in Human Hepatoblatoma Cells
title_full_unstemmed	Use of Biocompatible Sorafenib-gold Nanoconjugates for Reversal of Drug Resistance in Human Hepatoblatoma Cells
title_sort	use of biocompatible sorafenib-gold nanoconjugates for reversal of drug resistance in human hepatoblatoma cells
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/d0e4b84a554d47299fdab6cb2a459a2a
work_keys_str_mv	AT sandeepkumarvishwakarma useofbiocompatiblesorafenibgoldnanoconjugatesforreversalofdrugresistanceinhumanhepatoblatomacells AT priyankasharmila useofbiocompatiblesorafenibgoldnanoconjugatesforreversalofdrugresistanceinhumanhepatoblatomacells AT avinashbardia useofbiocompatiblesorafenibgoldnanoconjugatesforreversalofdrugresistanceinhumanhepatoblatomacells AT lakkireddychandrakala useofbiocompatiblesorafenibgoldnanoconjugatesforreversalofdrugresistanceinhumanhepatoblatomacells AT nraju useofbiocompatiblesorafenibgoldnanoconjugatesforreversalofdrugresistanceinhumanhepatoblatomacells AT gsravani useofbiocompatiblesorafenibgoldnanoconjugatesforreversalofdrugresistanceinhumanhepatoblatomacells AT bvssastry useofbiocompatiblesorafenibgoldnanoconjugatesforreversalofdrugresistanceinhumanhepatoblatomacells AT mdaejazhabeeb useofbiocompatiblesorafenibgoldnanoconjugatesforreversalofdrugresistanceinhumanhepatoblatomacells AT aleemahmedkhan useofbiocompatiblesorafenibgoldnanoconjugatesforreversalofdrugresistanceinhumanhepatoblatomacells AT marshaldhayal useofbiocompatiblesorafenibgoldnanoconjugatesforreversalofdrugresistanceinhumanhepatoblatomacells
_version_	1718394007359324160

Use of Biocompatible Sorafenib-gold Nanoconjugates for Reversal of Drug Resistance in Human Hepatoblatoma Cells

Ejemplares similares